Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Incidence and PD-L1 Expression of MET 14 Skipping in Chinese Population: A Non-Selective NSCLC Cohort Study Using RNA-Based Sequencing

1 Jun 2020

Abstract excerpt

Background: Mesenchymal–epithelial transition ( MET ) exon14 skipping mutations represent a clinically unique molecular subtype of NSCLC. The prevalence rates of MET exon 14 skipping in lung adenocarcinoma (ADC) range from 0.9% to 4.0% in Asian populations. Since some somatic variants that do not encompass the MET exon 14 splice sites might also induce MET exon 14 skipping, the RNA-based sequencing is speculated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Immune Cell Function and Interaction
Share to Immune cells in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32669854
DOI: 10.2147/ott.s241231

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Incidence and PD-L1 Expression of MET 14 Skipping in Chinese Population: A Non-Selective NSCLC Cohort Study Using RNA-Based SequencingPMID 32669854Read ↗

MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer.Semantic proximity Read ↗

Identification of MET exon14 skipping by targeted DNA- and RNA-based next-generation sequencing in pulmonary sarcomatoid carcinomas.Semantic proximity Read ↗

[MET Exon 14 Skipping Mutations in Non-small Cell Lung Cancer].Semantic proximity Read ↗

Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future ChallengesSemantic proximity Read ↗

[Expert Consensus on Targeted Therapy of NSCLC with MET Exon 14 Skipping Mutation].Semantic proximity Read ↗

MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes.Semantic proximity Read ↗

Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer - A systematic review and meta-analysis.Semantic proximity Read ↗

MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values.Semantic proximity Read ↗

MET exon 14 skipping mutations in non-small-cell lung cancer a 3 years screening experienceSemantic proximity Read ↗

Real world experience with MET inhibitors in MET exon 14 skipping mutated non-small cell lung cancer: largest Indian perspectiveSemantic proximity Read ↗

A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population.Semantic proximity Read ↗

MET Exon 14 Skipping Mutations in Non–Small-Cell Lung Cancer: Testing Considerations and Clinical Outcomes a 3 years screening experienceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.